Literature DB >> 21287296

Lupus nephritis in Colombians: contrasts and comparisons with other populations.

Juan-Manuel Anaya1, Carlos Cañas, Rubén D Mantilla, Ricardo Pineda-Tamayo, Gabriel J Tobón, Catalina Herrera-Diaz, Diego M Rendón, Adriana Rojas-Villarraga, Mauricio Uribe.   

Abstract

Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE) since it is the major predictor of poor prognosis. The purpose of this study was to examine the clinical and immunological characteristics associated with LN development during the course of SLE in Colombians. Therefore, patients with SLE followed at five different referral centers in Medellin, Bogota, and Cali were included in this cross-sectional and multicenter study. Factors influencing LN were assessed by conditional logistic regression analysis, adjusting by gender, age at onset, duration of disease, and city of origin. The entire sample population included 467 patients, of whom 51% presented with LN. The presence of anti-dsDNA antibodies (adjusted odds ratio (AOR), 2.06; 95% confidence interval (CI), 1.16-3.65), pleuritis (AOR, 3.82; 95% CI, 1.38-10.54), and hypertension (AOR, 2.63; 95% CI, 1.23-5.62) were positively associated with LN, whereas the presence of anti-La antibodies was a protective factor against LN development (AOR, 0.4; 95% CI, 0.19-0.85). A review of literature on LN in different populations is made. The identified clinical- and laboratory-associated factors would assist earlier diagnosis and guide decisions on therapeutic interventions on this critical and frequent complication of SLE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21287296     DOI: 10.1007/s12016-010-8249-4

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  47 in total

1.  Hopkins Lupus Cohort. 1999 update.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  2000-05       Impact factor: 2.670

2.  Protective role of rheumatoid factor in lupus nephritis.

Authors:  T L Skare; M B G Silva; A P Holler; P A Chavez
Journal:  Clin Exp Rheumatol       Date:  2009 Sep-Oct       Impact factor: 4.473

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture.

Authors:  G S Alarcón; A W Friedman; K V Straaton; J M Moulds; J Lisse; H M Bastian; G McGwin; A A Bartolucci; J M Roseman; J D Reveille
Journal:  Lupus       Date:  1999       Impact factor: 2.911

5.  Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone.

Authors:  K E Moss; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-08       Impact factor: 7.580

6.  Ethnic differences in the clinical expression of systemic lupus erythematosus: a comparative study between African-Americans and Latin Americans.

Authors:  J F Molina; J Molina; C García; A E Gharavi; W A Wilson; L R Espinoza
Journal:  Lupus       Date:  1997       Impact factor: 2.911

7.  Delayed lupus nephritis.

Authors:  D-C Varela; G Quintana; E C Somers; A Rojas-Villarraga; G Espinosa; M-E Hincapie; W J McCune; R Cervera; J-M Anaya
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

8.  Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients.

Authors:  S Malik; G R Bruner; C Williams-Weese; L Feo; R Hal Scofield; M Reichlin; J B Harley; A H Sawalha
Journal:  Lupus       Date:  2007       Impact factor: 2.911

9.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

10.  Prognostic determinants in lupus nephritis: a long-term clinicopathologic study.

Authors:  J V Donadio; G M Hart; E J Bergstralh; K E Holley
Journal:  Lupus       Date:  1995-04       Impact factor: 2.911

View more
  11 in total

1.  NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis.

Authors:  Anupam Guleria; Avadhesh Pratap; Durgesh Dubey; Atul Rawat; Smriti Chaurasia; Edavalath Sukesh; Sanat Phatak; Sajal Ajmani; Umesh Kumar; Chunni Lal Khetrapal; Paul Bacon; Ramnath Misra; Dinesh Kumar
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

Review 2.  Lupus nephritis: an update.

Authors:  Tasnim F Imran; Frederick Yick; Suneet Verma; Christopher Estiverne; Chinonye Ogbonnaya-Odor; Srikanth Thiruvarudsothy; Alluru S Reddi; Neil Kothari
Journal:  Clin Exp Nephrol       Date:  2015-10-16       Impact factor: 2.801

3.  Mechanisms and pathophysiology of autoimmune disease.

Authors:  Wesley H Brooks
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

4.  miRNA-451a Targets IFN Regulatory Factor 8 for the Progression of Systemic Lupus Erythematosus.

Authors:  Jia Cheng; Rui Wu; Li Long; Jiang Su; Jian Liu; Xiao-Dan Wu; Jing Zhu; Bin Zhou
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

5.  Lupus nephritis: an overview of recent findings.

Authors:  Alberto de Zubiria Salgado; Catalina Herrera-Diaz
Journal:  Autoimmune Dis       Date:  2012-03-22

Review 6.  Prevalence of celiac disease in latin america: a systematic review and meta-regression.

Authors:  Rafael Parra-Medina; Nicolás Molano-Gonzalez; Adriana Rojas-Villarraga; Nancy Agmon-Levin; Maria-Teresa Arango; Yehuda Shoenfeld; Juan-Manuel Anaya
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

7.  The coexistence of antiphospholipid syndrome and systemic lupus erythematosus in Colombians.

Authors:  Juan-Sebastian Franco; Nicolás Molano-González; Monica Rodríguez-Jiménez; Yeny Acosta-Ampudia; Rubén D Mantilla; Jenny Amaya-Amaya; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

8.  Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3.

Authors:  Masahiro Moritoki; Takeshi Kadowaki; Toshiro Niki; Daisuke Nakano; Genichiro Soma; Hirohito Mori; Hideki Kobara; Tsutomu Masaki; Masakazu Kohno; Mitsuomi Hirashima
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

9.  Renal transplantation in systemic lupus erythematosus: outcome and prognostic factors in 50 cases from a single centre.

Authors:  Ernesto Cairoli; Carolina Sanchez-Marcos; Gerard Espinosa; Constanza Glucksmann; Guadalupe Ercilla; Federico Oppenheimer; Ricard Cervera
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

10.  Very delayed lupus nephritis: a report of three cases and literature review.

Authors:  André R Alexandre; Pedro L Carreira; David A Isenberg
Journal:  Lupus Sci Med       Date:  2018-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.